Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

LBRX vs LMRI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LBRX Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 8–0 Matrix Metrics)

LBRX Overall Winner 6-Pillar Tally: LBRX 4 – 0 LMRI (2 Tie) Matrix Metrics: LBRX 8 – 0 LMRI

As of Nov 20, 2026, LB Pharmaceuticals Inc (LBRX) is the stronger overall head-to-head candidate over LMRI (LMRI) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). LBRX carries a Unified Composite Score of 38.2/100 (SELL) at $38.85 (N/M Forward P/E, 0.0% operating margin), whereas LMRI carries 32.1/100 (SELL) at $14.26 (N/M Forward P/E, N/A operating margin).

  • Defensive Composite Rating Caution: Although LBRX compares more favorably head-to-head, both LBRX (38.2/100 SELL) and LMRI (32.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: LBRX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 43.8); meanwhile LMRI trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LBRX vs LMRI
LBRX NASDAQ Head-to-Head Winner
LB Pharmaceuticals Inc Common Stock
Pharmaceutical Preparations
$38.85
-2.97% 1D
Market Cap $1.3B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.07β · 60% Vol
Unified Composite Score
38.2 / 100 SELL
Tech 20.0 Fund 36.0 Flow 54.0 Mom 40.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -6.4%) with fading momentum, RSI 44
RSI-14: 43.8 · SMA20: $41.07 · SMA50: $39.49
LMRI US Equity
LMRI
Institutional Equity
$14.26
+1.42% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.22β · 85% Vol
Unified Composite Score
32.1 / 100 SELL
Tech 50.0 Fund 30.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.4% over 20 days), RSI 63
RSI-14: 62.5 · SMA20: $13.28 · SMA50: $11.73

6-Pillar Scorecard Institutional Category Breakdown (LBRX 4 – 0 LMRI)

Columns: Metric · LBRX · LMRI
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale LBRX
Revenue Growth (YoY) +0.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) N/A N/A
Market Cap $1.3B N/A
3. Profitability & Quality LBRX
Gross Margin N/A N/A
Operating Margin 0.0% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -38.8% N/A
4. Balance Sheet & Cash Flow LBRX
Cash Generation (TTM) -$144M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $210M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LBRX
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 78.9% (4th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Distribution NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LBRX (8) vs LMRI (0)
Institutional Metric LBRX LMRI Criterion Row Edge
Market Capitalization
Scale
$1.3B N/A Larger Scale LBRX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% N/A Higher Growth LBRX
Operating Margin (TTM)
Profitability
0.0% N/A Higher Margin LBRX
Net Profit Margin
Profitability
0.0% N/A Higher Margin LBRX
Return on Equity (ROE)
Capital Efficiency
-38.8% N/A Higher ROE LBRX
52-Week Range Position
Momentum
68% ($15–$50) 60% ($6–$19) Stronger Trend LBRX
Beta / 30D Volatility
Risk Regime
1.07β · 60% Vol 1.22β · 85% Vol Lower Realized Risk LBRX
Unified Institutional Score
Composite Signal
38.2 / 100 (SELL) 32.1 / 100 (SELL) Higher Composite LBRX
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$144M ($210M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LMRI +32.4 pp
LBRX: -1.45% · LMRI: +30.95%
3M Horizon LMRI +39.76 pp
LBRX: -19.42% · LMRI: +20.34%
6M Horizon LMRI +40.09 pp
LBRX: +38.16% · LMRI: +78.25%
1Y Horizon LBRX +115.04 pp
LBRX: +92.04% · LMRI: -23.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LBRX vs LMRI. Trailing 12-month operating profitability (LBRX 0.0% vs LMRI N/A) and valuation multiples (LBRX N/M vs LMRI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

LBRX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-38.8% · N/M
LMRI ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LBRX CONSOLIDATION
66d in phase · OBV DISTRIBUTION
Current IV 78.9%
IV Percentile 4th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact LBRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LMRI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LMRI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LBRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LMRI Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LBRX vs LMRI Key Questions & Quantitative Answers

As of Nov 20, 2026, LB Pharmaceuticals Inc (LBRX) is the stronger overall head-to-head candidate over LMRI (LMRI) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). LBRX carries a Unified Composite Score of 38.2/100 (SELL) at $38.85 (N/M Forward P/E, 0.0% operating margin), whereas LMRI carries 32.1/100 (SELL) at $14.26 (N/M Forward P/E, N/A operating margin). Defensive Composite Rating Caution: Although LBRX compares more favorably head-to-head, both LBRX (38.2/100 SELL) and LMRI (32.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: LBRX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 43.8); meanwhile LMRI trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LBRX leads the Growth & Scale pillar: LBRX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LMRI at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, LBRX generates N/A in USD-normalized revenue versus N/A for LMRI. In operating R&D and SG&A reinvestment, LBRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LMRI.

LBRX and LMRI trade at balanced relative valuation multiples. LBRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LMRI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LBRX (-38.8% ROE) versus LMRI (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, LBRX carries 78.9% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 60% Vol realized risk). By comparison, LMRI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.22β · 85% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.